Legal & Regulatory Bulletin – Issue No. 29, June/July 2020

This issue of the EMPEA Legal and Regulatory Bulletin comes at a time when our industry and the markets where we invest are facing particular challenges due to the impact of the COVID-19 pandemic. EMPEA members, including members of the Legal and Regulatory Council, have provided some of their insights… Read More

Janchor Partners, RA Capital, Hillhouse Capital, and Jiashan SDIC Invest USD310m Series C for Chinese Drug Developer Everest Medicines

Janchor Partners, RA Capital Management, Hillhouse Capital, and Jiashan SDIC have invested a USD310m Series C for China-based biopharmaceutical company Everest Medicines, with participation from Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, and Octagon Investments. Existing backers CBC Group, Cormorant Asset Management, Pavilion Capital, and… Read More

Hillhouse Leads USD160m Series B for Chinese Biopharma Genor

Hillhouse Capital led a USD160m Series B for China-based biopharmaceutical company Genor Biopharma, with participation from Temasek Holdings, Haitong Capital, Cavenham PE, and CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group. Read more… Read More



(default archive template)